[Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis].

CONCLUSION: The analysis of the French pharmacovigilance database cases allows to confirm an expected and monitored risk profile in the risk management plan for both drugs. Several signals have arisen, some of which will be investigated through a pharmacoepidemiology study.
PMID: 33376005 [PubMed - as supplied by publisher]

Source: Therapie - December 13, 2020 Category: Psychiatry & Psychology Authors: Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E, et le réseau français des Centres régionaux de pharmacovigilance Tags: Therapie Source Type: research